New Three-Drug cocktail takes on tough melanoma

NCT ID NCT05926960

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a three-drug combination (encorafenib, binimetinib, and pembrolizumab) works better than a two-drug combo (ipilimumab and nivolumab) for people with advanced melanoma that has a BRAF mutation and has already been treated with anti-PD-1 therapy. The trial was terminated early after enrolling only 38 participants, so the results are limited. The goal was to see which approach shrinks tumors more effectively and helps people live longer without their cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

encorafenib, binimetinib, and pembrolizumab (drug combination)

What this could lead to

If this combination works better than the standard two-drug approach, it could offer a new treatment option for people with advanced melanoma that has a BRAF mutation and has stopped responding to initial immunotherapy.

What could go wrong

This trial was terminated early with only 38 participants, so results are limited and may not be reliable. Combining three drugs also raises the risk of more severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Show contact details

Locations

A.O.U. Policlinico Paolo Giaccone

Palermo, Sicily, 90127, Italy
AO Santa Maria della Misericordia

Perugia, Umbria, 06132, Italy
Azienda Ospedaliero Universitaria Senese

Siena, Tuscany, 53100, Italy
Fachklinik Hornheide

Münster, North Rhine-Westphalia, 48157, Germany
Hospital General Universitario Gregorio Marañon

Madrid, 28007, Spain
Hospital General Universitario de Valencia

Valencia, Valenciana, Comunitat, 46014, Spain
Hospital Germans Trias i Pujol

Badalona, Barcelona [barcelona], 08916, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [barcelona], 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Miguel Servet

Zaragoza, 50009, Spain
Institut Català d'Oncologia - L'Hospitalet

L'Hospitalet de Llobregat, Catalunya [cataluña], 08908, Spain
Istituto Europeo di Oncologia IRCCS

Milan, 20141, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale

Naples, 80131, Italy
Istituto Nazionale Tumori Regina Elena

Rome, ROMA, 00144, Italy
Istituto Oncologico Veneto IRCCS

Padova, Veneto, 35128, Italy
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia

Candiolo, Torino, 10060, Italy
Medizinische Hochschule Hannover

Hanover, Lower Saxony, 30625, Germany
Narodny onkologicky ustav

Bratislava, 833 10, Slovakia
Neovizia, s.r.o.

Bratislava, 85101, Slovakia
Pratia MCM Krakow

Krakow, 30-727, Poland
Universitaetsklinikum Essen

Essen, North Rhine-Westphalia, 45147, Germany
Universitaetsklinikum Tuebingen

Tübingen, Baden-Wurttemberg, 72076, Germany
Universitätsklinikum Schleswig-Holstein

Lübeck, Schleswig-Holstein, 23538, Germany
Universitätsmedizin Johannes Gutenberg Universität Mainz

Mainz, Rhineland-Palatinate, 55131, Germany